

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0164US1	Application No. 10/582,413
	Applicant Toshihiko Ohtomo <i>et al.</i>		
	Filing Date October 26, 2006	Group Art Unit 1643	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	4,946,778	08/1990	Ladner <i>et al.</i>			
	2	5,789,554	08/1998	Leung <i>et al.</i>			
	3	5,837,242	11/1998	Holliger <i>et al.</i>			
	4	5,840,344	11/1998	Fukushima			
	5	5,885,574	03/1999	Elliott			
	6	6,126,980	10/2000	Smith <i>et al.</i>			
	7	6,579,692	06/2003	Fukushima			
	8	6,719,972	04/2004	Gribben <i>et al.</i>			
	9	6,759,043	07/2004	Fukushima			
	10	7,115,373	10/2006	Hashida <i>et al.</i>			
	11	7,456,260	11/2008	Rybak <i>et al.</i>			
	12	2003/0147894	08/2003	Fukushima <i>et al.</i>			
	13	2003/0157100	08/2003	Fukushima <i>et al.</i>			
	14	2003/0157577	08/2003	Fukushima <i>et al.</i>			
	15	2003/0202975	10/2003	Tedder			
	16	2003/0211108	11/2003	Fukushima <i>et al.</i>			
	17	2004/0001828	01/2004	Tuscano <i>et al.</i>			
	18	2004/0073013	04/2004	Fukushima <i>et al.</i>			
	19	2008/0248037	10/2008	Li <i>et al.</i>			
	20	2009/0022687	01/2009	Matsumoto <i>et al.</i>			
	21	2009/0028854	01/2009	Igawa <i>et al.</i>			
	22	2009/0117097	05/2009	Igawa <i>et al.</i>			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	23	EP 0 721 015	07/10/1996	Europe				
	24	EP 1 035 132	09/13/2000	Europe				

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0164US1	Application No. 10/582,413
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Toshihiko Ohtomo <i>et al.</i>	
		Filing Date October 26, 2006	Group Art Unit 1643

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	25	EP 1 327 681	07/16/2003	Europe				
	26	EP 1 396 500	03/10/2004	Europe				
	27	EP 1 262 548	08/10/2008	Europe				
	28	JP 7236475	09/12/1995	Japan			Abstract only	
	29	JP 11-092500	04/06/1999	Japan			Abstract only	
	30	JP 2000-95800	04/04/2000	Japan			Abstract only	
	31	WO 91/16928	11/14/1991	WIPO				
	32	WO 92/19759	11/12/1992	WIPO			English abstract	
	33	WO 94/13806	06/23/1994	WIPO				
	34	WO 96/36360	11/21/1996	WIPO				
	35	WO 97/01633	01/16/1997	WIPO				
	36	WO 97/32601	09/12/1997	WIPO			English abstract	
	37	WO 98/44001	08/10/1998	WIPO				
	38	WO 99/12973	03/18/1999	WIPO			English abstract	
	39	WO 99/17364	04/08/1999	WIPO				
	40	WO00/53634	09/14/2000	WIPO			English abstract	
	41	WO00/75191	12/14/2000	WIPO				
	42	WO01/77342	10/18/2001	WIPO				
	43	WO 01/87337	11/22/2001	WIPO				
	44	WO02/094880	11/28/2002	WIPO			English abstract	
	45	WO 02/097033	12/05/2002	WIPO				
	46	WO 2004/003019	01/08/2004	WIPO				

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>14875-0164US1</b>	Application No. <b>10/582,413</b>
		Applicant <b>Toshihiko Ohtomo <i>et al.</i></b>	
		Filing Date <b>October 26, 2006</b>	Group Art Unit <b>1643</b>

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	47	ARNDT <i>et al.</i> , "Factors Influencing the Dimer to Monomer Transition of an Antibody Single-Chain Fv Fragment," <i>Biochemistry</i> , 37:12918-12926 (1998)
	48	AVENT <i>et al.</i> , "Monoclonal antibodies that recognize different membrane proteins that are deficient in Rhnull human erythrocytes. One group of antibodies reacts with a variety of cells and tissues whereas the other group is erythroid-specific," <i>Biochem. J.</i> , 251:499-505 (1988)
	49	BARTLEY <i>et al.</i> , "Identification and Cloning of a Megakaryocyte Growth and Development Factor That is a Ligand for the Cytokine Receptor Mpl," <i>Cell</i> , 77:1117-1124 (1994)
	50	BAZIL <i>et al.</i> , "Apoptosis of human hematopoietic progenitor cells induced by crosslinking of surface CD43, the major sialoglycoprotein of leukocytes," <i>Blood</i> , 86:502-511 (1995)
	51	BAZZONI <i>et al.</i> , "Chimeric tumor necrosis factor receptors with constitutive signaling activity," <i>Proc. Natl. Acad. Sci. USA</i> , 92(12):5376-5580 (1995)
	52	BERESFORD <i>et al.</i> , "Binding Characteristics and Tumor Targeting of a Covalently Linked Divalent CC49 Single-Chain Antibody," <i>Int. J. Cancer</i> , 81:911-917 (1999)
	53	BERGER <i>et al.</i> , "Inhibition of intractable nucleases with ribonucleoside-vanadyl complexes: isolation of messenger ribonucleic acid from resting lymphocytes," <i>Biochemistry</i> , 18(23):5143-5149 (1979)
	54	BODMER <i>et al.</i> , "TRAIL Receptor-2 Signals Apoptosis Through FADD and Caspase-8," <i>Nat. Cell Biol.</i> , 2:241-243 (2000)
	55	BORDEN <i>et al.</i> , "Lymphokines and Cytokines as Cancer Treatment," <i>Cancer</i> , 65:800-814 (1990)
	56	BOWIE <i>et al.</i> , "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," <i>Science</i> , 247:1306-1310 (1990)
	57	BROWN <i>et al.</i> , "Integrin-associated protein: a 50-kD plasma membrane antigen physically and functionally associated with integrins," <i>J. Cell Biology</i> , 111(6 Pt 1):2785-2794 (1990)
	58	BROWN <i>et al.</i> , "Integrin-associated protein (CD47) and its ligands," <i>Trends Cell Biology</i> , 11(3):130-135 (2001)
	59	BUCHSBAUM <i>et al.</i> , "Antitumor Efficacy of TRA-8 Anti-DR5 Monoclonal Antibody Alone or in Combination with Chemotherapy and/or Radiation Therapy in a Human Breast Cancer Model," <i>Clin. Cancer Res.</i> , 9:3731-3741 (2003)
	60	BURGESS <i>et al.</i> , "Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue," <i>J. Cell Biol.</i> , 111:2129-2138 (1990)
	61	BURTHEM <i>et al.</i> , "Hairy cell interactions with extracellular matrix: expression of specific integrin receptors and their role in the cell's response to specific adhesive proteins," <i>Blood</i> , 84(3):873-882 (1994)
	62	BYERS, "What Can Randomized Controlled Trials Tell us About Nutrition and Cancer Prevention?," <i>CA Cancer J. Clin.</i> , 49:353-361 (1999)
	63	CALDAS <i>et al.</i> , "Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen," <i>Mol. Immunol.</i> , 39:941-952 (2003)
	64	CARON <i>et al.</i> , "Engineered Humanized Dimeric Forms of IgG Are More Effective Antibodies," <i>J. Exp. Med.</i> , 176:1191-1195 (1992)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0164US1	Application No. 10/582,413
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Toshihiko Ohtomo <i>et al.</i>	
		Filing Date October 26, 2006	Group Art Unit 1643

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	65	CHIEN <i>et al.</i> , "Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: Proposal of a structural mechanism," <i>Proc. Nat. Acad. Sci. USA</i> , 86:5532-5536 (1989)
	66	CHIRGWIN <i>et al.</i> , "Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease," <i>Biochemistry</i> , 18(24):5294-5299 (1979)
	67	CHUNTHARAPAI <i>et al.</i> , "Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4," <i>J. Immunol.</i> , 166:4891-4898 (2001)
	68	COCHLOVIUS <i>et al.</i> , "Cure of Burkitt's Lymphoma in Severe Combined Immunodeficiency Mice by T Cells, Tetravalent CD3 x CD19 Tandem Diabody and CD28 Costimulation," <i>Cancer Res.</i> , 60:4336-4341 (2000)
	69	COOPER <i>et al.</i> , "Transendothelial migration of neutrophils involves integrin-associated protein (CD47)," <i>Proc. Natl. Acad. Sci. USA</i> , 92:3978-3982 (1995)
	70	DANIEL <i>et al.</i> , "Pathway of apoptosis induced in Jurkat T Lymphoblasts by anti-HLA Class I antibodies," <i>Human Immunology</i> , 65(3):189-199 (2004)
	71	DE LEON <i>et al.</i> , "High resolution human leukocyte antigen (HLA) class I and class II allele typing in Mexican mestizo women with sporadic breast cancer: case-control study," <i>BMC Cancer</i> , 9(48):1-9 (2009)
	72	DEGLI-ESPOSTI <i>et al.</i> , "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family," <i>J. Exp. Med.</i> , 186:1165-1170 (1997)
	73	DE SAUVAGE <i>et al.</i> , "Stimulation of Megakaryocytopoiesis and Thrombopoiesis by the c-Mpl Ligand," <i>Nature</i> , 369:533-538 (1994)
	74	DESPLANCQ <i>et al.</i> , "Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3," <i>Protein Engineering</i> , 7(8):1027-1033 (1994)
	75	DE ST. GROTH <i>et al.</i> , "Production of Monoclonal Antibodies: Strategy and Tactics," <i>Journal of Immunological Methods</i> , 35:1-21 (1980)
	76	DILLMAN, "Monoclonal antibodies for treating cancer," <i>Ann. Int. Med.</i> , 11(7):592-603 (1989)
	77	DORAI <i>et al.</i> , "Mammalian cell expression of single-chain Fv (sFv) antibody proteins and their C-terminal fusions with interleukin-2 and other effector domains," <i>Biotechnology</i> , 12(9):890-897 (1994)
	78	DUFNER <i>et al.</i> , "Harnessing phage and ribosome display for antibody optimization," <i>Trends Biotechnol.</i> , 24(11):523-529 (2006)
	79	EMERY <i>et al.</i> , "Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL," <i>J. Biol. Chem.</i> , 273:14363-14367 (1998)
	80	FELGENHAUER <i>et al.</i> , "Nucleotide Sequences of the cDNAs Encoding the V-Regions of H- and L-Chains of a Human Monoclonal Antibody Specific to HIV-1 - gp41," <i>Nucleic Acids Research</i> , 18(16):4927 (1990)
	81	FUJIMOTO <i>et al.</i> , "50-kD integrin-associated protein does not detectably influence several functions of glycoprotein IIb-IIIa complex in human platelets," <i>Blood</i> , 86(6):2174-2182 (1995)
	82	FUKUSHIMA <i>et al.</i> , "Enhanced hematopoiesis in vivo and in vitro by splenic stromal cells derived from the mouse with recombinant granulocyte colony-stimulating factor," <i>Blood</i> , 80(8):1914-1922 (1992)
	83	FUKUSHIMA <i>et al.</i> , "Apoptosis of Bone Marrow Cells Via Integrin Associated Protein by the Novel Monoclonal Antibody," <i>Blood</i> , 94(10):479A (1999)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0164US1	Application No. 10/582,413
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Toshihiko Ohtomo <i>et al.</i>	
		Filing Date October 26, 2006	Group Art Unit 1643

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	84	GALFRE <i>et al.</i> , "Preparation of monoclonal antibodies: strategies and procedures," <i>Methods in Enzymology</i> , 73:3-46 (1981)
	85	GALFRE <i>et al.</i> , "Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG," <i>Nature</i> , 277:131-133 (1979)
	86	GIUSTI <i>et al.</i> , "Somatic diversification of S107 from an antiphosphocholine to an anti-DNA autoantibody is due to a single base change in its heavy chain variable region," <i>Proc. Natl. Acad. Sci. USA</i> , 84:2926-2930 (1987)
	87	GODING, "Monoclonal Antibodies: Principles and Practice," <i>Academic Press</i> , second Ed., 125:129 (1986)
	88	GRANZIERO <i>et al.</i> , "Adoptive immunotherapy prevents prostate cancer in a transgenic animal model," <i>Eur. J. Immunol.</i> , 29:1127-1138 (1999)
	89	GREENSPAN <i>et al.</i> , "Defining epitopes: It's not as easy as it seems," <i>Nature Biotechnology</i> , 17:936-937 (1999)
	90	GRELL <i>et al.</i> , "TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytotoxicity," <i>Lymphokine and Cytokine Research</i> , 12(3):143-148 (1993)
	91	GRIFFITH <i>et al.</i> , "Functional Analysis of TRAIL Receptors Using Monoclonal Antibodies," <i>J. Immunol.</i> , 162:2597-2605 (1999)
	92	GÜSSOW and SEEMANN, "Humanization of Monoclonal Antibodies," <i>Methods in Enzymology</i> , 203:99-121 (1991)
	93	HOLLIGER <i>et al.</i> , "Specific Killing of Lymphoma Cells by Cytotoxic T-Cells Mediated by a Bispecific Diabody," <i>Protein Engineering</i> , 9(3):299-305 (1996)
	94	HOPP <i>et al.</i> , "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification," <i>Biotechnology</i> , 6:1204-1210 (1988)
	95	HORAN <i>et al.</i> , "Dimerization of the extracellular domain of granulocyte-colony stimulating factor receptor by ligand binding: a monovalent ligand induces 2:2 complexes," <i>Biochemistry</i> , 35:4886-4896 (1996)
	96	HUSTON <i>et al.</i> , "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in <i>Escherichia Coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 85:5879-5883 (1988)
	97	ICHIKAWA <i>et al.</i> , "Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity," <i>Nat. Med.</i> , 7:954-960 (2001)
	98	ITOH <i>et al.</i> , "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis," <i>Cell</i> , 66:233-243 (1991)
	99	JONES <i>et al.</i> , "Rapid PCR-Cloning of Full-Length Mouse Immunoglobulin Variable Regions," <i>Biotechnology</i> , 9:88-89 (1991)
	100	KEARNEY, <i>et al.</i> , "A New Mouse Myeloma Cell Line That Has Lost immunoglobulin Expression But Permits The Construction of Antibody-Secreting Hybrid Cells Lines," <i>The Journal of Immunology</i> , 123(4):1548-1550 (1979)
	101	KEEN <i>et al.</i> , "The use of serum-free medium for the production of functionally active humanized monoclonal antibody from NSO mouse myeloma cells engineered using glutamine synthetase as a selectable marker," <i>Cytotechnology</i> , 18(3):207-217 (Abstract) (1994)
	102	KIPRIYANOV <i>et al.</i> , "Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells," <i>In. J. Cancer</i> , 77:763-772 (1998)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>14875-0164US1</b>	Application No. <b>10/582,413</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>Toshihiko Ohtomo <i>et al.</i></b>	
		Filing Date <b>October 26, 2006</b>	Group Art Unit <b>1643</b>

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	103	KOHLER, <i>et al.</i> , "Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion," <i>Eur. J. Immunol.</i> , 6:511-519 (1976)
	104	KORTT <i>et al.</i> , "Recombinant anti-sialidase single-chain variable fragment antibody: Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex," <i>Eur. J. Biochem.</i> , 221:151-157 (1994)
	105	KORTT <i>et al.</i> , "Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten- residue linkers form dimmers and with zero-residue linker a trimer," <i>Protein Engineering</i> , 10(4):423-433 (1997)
	106	KOZAK, M., "At Least Six Nucleotides Preceding the AUG Initiator Codon Enhance Translation in Mammalian Cells," <i>J. Mol. Biol.</i> , 196:947-950 (1987)
	107	KUMAR <i>et al.</i> , "Molecular cloning and expression of the fabs of human autoantibodies in <i>Escherichia coli</i> ," <i>The Journal of Biological Chemistry</i> , 275(41):35129-35136 (2000)
	108	LARRICK, <i>et al.</i> , "Polymerase Chain Reaction Using Mixed Primers: Cloning of Human Monoclonal Antibody Variable Region Genes From Single Hybridoma Cells," <i>Biotechnology</i> , 7:934-938 (1989)
	109	LAW <i>et al.</i> , "Observations On The Effect Of A Folic-Acid Antagonist On Transplantable Lymphoid Leukemias In Mice," <i>Journal of the National Cancer Institute</i> , 10:179-193 (1949)
	110	LAZAR <i>et al.</i> , "Transforming growth factor $\alpha$ : mutation of aspartic acid 47 and leucine 48 results in different biological activities," <i>Molecular and Cellular Biology</i> , 8:1247-1252 (1988)
	111	LEI <i>et al.</i> , "Characterization of the <i>Erwinia Carotovora pelB</i> Gene and Its Product Pectate Lyase," <i>Journal of Bacteriology</i> , 169:4379-4383 (1987)
	112	LIN <i>et al.</i> , "Structure-function relationships in glucagon: properties of highly purified des-His-1-, monoiodo-, and (des-Asn-28, Thr-29)(homoserine lactone-27)-glucagon," <i>Biochemistry</i> , 14:1559-1563 (1975)
	113	LINDBERG <i>et al.</i> , "Molecular Cloning of Integrin-Associated Protein: An Immunoglobulin Family Member with Multiple Membrane-Spanning Domains Implicated in $\alpha_v\beta_3$ -Dependent Ligand Binding," <i>The Journal of Cell Biology</i> , 123(2):485-496, The Rockefeller University Press (1993)
	114	LINDBERG <i>et al.</i> , "Rh-Related Antigen CD47 is the Signal-Transducer Integrin-Associated Protein," <i>J. Biol. Chem.</i> , 269:1567-1570 (1994)
	115	MARGULIES <i>et al.</i> , "Somatic Cell Hybridization of Mouse Myeloma Cells," <i>Cell</i> , 8:405-415 (1976)
	116	MARIUZZA <i>et al.</i> , "The structural basis of antigen-antibody recognition," <i>Annu. Rev. Biophys. Biophys. Chem.</i> , 16:139-159 (1987)
	117	MARSTERS <i>et al.</i> , "A Novel Receptor for Apo2L/TRAIL Contains a Truncated Death Domain," <i>Curr. Biol.</i> , 7:1003-1006 (1997)
	118	MATEO <i>et al.</i> , "Induction of Apoptosis in B-Cells From Chronic Lymphocytic Leukemia (B-CLLs) by CD47," <i>FASEB Journal</i> , 12(5):A1082 (1998)
	119	MATEO <i>et al.</i> , "CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia," <i>Nat. Med.</i> , 5(11):1277-1284 (1999)
	120	MAWBY <i>et al.</i> , "Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumor marker OA3," <i>Biochem. J.</i> , 304:525-530 (1994)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0164US1	Application No. 10/582,413
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Toshihiko Ohtomo <i>et al.</i>	
		Filing Date October 26, 2006	Group Art Unit 1643

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	121	METHIA <i>et al.</i> , "Oligodeoxynucleotides Antisense to the Proto-Oncogene <i>c-Mpl</i> Specifically Inhibit In Vitro Megakaryocytopoiesis," <i>Blood</i> , 82(5):1395-1401 (1993)
	122	MILILI <i>et al.</i> , "The VDJ Repertoire Expressed in Human preB Cells Reflects the Selection of <i>Bona Fide</i> Heavy Chains," <i>Eur. J. Immunol.</i> , 26:63-69 (1996)
	123	MIZUSHIMA <i>et al.</i> , "pEF-BOS, a Powerful Mammalian Expression Vector," <i>Nucleic Acids Research</i> , 18(17):5322 (1990)
	124	MOORE <i>et al.</i> , "Kinetics and thermodynamics of dimer formation and dissociation for a recombinant humanized monoclonal antibody to vascular endothelial growth factor," <i>Biochemistry</i> , 38:13960-13967 (1999)
	125	MORI <i>et al.</i> , "Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2," <i>Cell Death and Differentiation</i> , 11:203-207 (2004)
	126	MULLIGAN <i>et al.</i> , "Synthesis of Rabbit $\beta$ -Globin in Cultured Monkey Kidney Cells Following Infection with a SV40 $\beta$ -Globin Recombinant Genome," <i>Nature</i> , 277:108-114 (1979)
	127	NAKAYAMA <i>et al.</i> , "Thrombocytosis in preterm infants: a possible involvement of thrombopoietin receptor gene expression," <i>Journal of Molecular Medicine</i> , 83:316-320 (2005)
	128	NGO <i>et al.</i> , "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz, Jr. <i>et al.</i> Editors, Birkhauser Boston, 433-506 (1994)
	129	O'BRIEN <i>et al.</i> , "Monoclonal antibodies for the human insulin receptor stimulate intrinsic receptor-kinase activity," <i>Biochim. Soc. Trans.</i> , 14(6):1021-1023 (1986)
	130	OHTSUKA <i>et al.</i> , "Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway," <i>Oncogene</i> , 22:2034-2044 (2003)
	131	PAN <i>et al.</i> , "An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL," <i>Science</i> , 277:815-818 (1997)
	132	PAN <i>et al.</i> , "The Receptor for the Cytotoxic Ligand TRAIL," <i>Science</i> , 276:111-113 (1997)
	133	PAUL, <i>Fundamental Immunology</i> , Raven Press, NY, Chapter 8, p. 242 (1993)
	134	PAUL, <i>Fundamental Immunology</i> , 3rd Edition, Raven Press, NY, Chapter 8, pp. 292-295 (1993)
	135	PETTERSON <i>et al.</i> , "CD47 Signals T Cell Death," <i>J. Immunol.</i> , 7031-7040 (1999)
	136	PETTERSON, "CD47 and death signaling in the immune system," <i>Apoptosis</i> , 5:299-306 (2000)
	137	REINHOLD <i>et al.</i> , "In vivo expression of alternatively spliced forms of integrin-associated protein (CD47)," <i>J. Cell Science</i> , 108:3419-3425 (1995)
	138	RIECHMANN <i>et al.</i> , "Reshaping Human Antibodies for Therapy," <i>Nature</i> , 332:323-327 (1988)
	139	REITER <i>et al.</i> , "Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv," <i>Protein Engineering</i> , 7(5):697-704 (1994)
	140	REITER <i>et al.</i> , "Stabilization of the Fv Fragments in Recombinant Immunotoxins by Disulfide Bonds Engineered into Conserved Framework Regions," <i>Biochemistry</i> , 33:5451-5459 (1994)
	141	ROUE <i>et al.</i> , "Mitochondrial dysfunction in CD47-mediated caspase-independent cell death: ROS production in the absence of cytochrome c and AIF release," <i>Biochimie.</i> , 85:741-746 (2003)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0164US1	Application No. 10/582,413
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Toshihiko Ohtomo <i>et al.</i>	
		Filing Date October 26, 2006	Group Art Unit 1643

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	142	ROZSNYAY <i>et al.</i> , "Phenylarsine oxide (PAO) blocks antigen receptor-induced calcium response and tyrosine phosphorylation of a distinct group of proteins," <i>Immunology Lett.</i> , 37(2-3):197-205 (1993)
	143	SACKSTEIN, "The lymphocyte homing receptors: gatekeepers of the multistep paradigm," <i>Current Opinion in Hematology</i> , 12:444-450 (2005)
	144	SATO <i>et al.</i> , "Reshaping a Human Antibody to Inhibit the Interleukin 6-Dependent Tumor Cell Growth," <i>Cancer Research</i> , 53:851-856 (1993)
	145	SCHICKEL, <i>et al.</i> , "Gene for Integrin-Associated Protein (IAP, CD47): Physical Mapping, Genomic Structure, and Expression Studies in Skeletal Muscle," <i>Biochem. Cell. Biol.</i> , 80(2):169-176 (2002)
	146	SCHWARTZ <i>et al.</i> , "A superactive insulin: [B10-aspartic acid]insulin(human)," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 84:6408-6411 (1987)
	147	SCHWARTZ <i>et al.</i> , "A 50-kDa Integrin-associated Protein Is Required for Integrin-regulated Calcium Entry in endothelial Cells," <i>J. Biol. Chem.</i> , 268(27):19931-19934 (1993)
	148	SCHMIDT <i>et al.</i> , "A bivalent single-chain antibody-toxin specific for ErbB-2 and the EGF receptor," <i>Int. J. Cancer</i> , 65(4):538-546 (1996)
	149	SHERIDAN <i>et al.</i> , "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors," <i>Science</i> , 277:818-821 (1997)
	150	SHIGETA <i>et al.</i> , "Sperm-immobilizing monoclonal antibody to human seminal plasma antigens," <i>Clin. Exp. Immunol.</i> , 42:458-462 (1980)
	151	SHULMAN <i>et al.</i> , "A better cell line for making hybridomas secreting specific antibodies," <i>Nature</i> , 276:269-270 (1978)
	152	SMITH-GILL <i>et al.</i> , "Contributions of immunoglobulin heavy and light chains to antibody specificity for lysozyme and two haptens," <i>The Journal of Immunology</i> , 139:4135-4144 (1987)
	153	SONG <i>et al.</i> , "Light chain of natural antibody plays a dominant role in protein antigen binding," <i>Biochemical and Biophysical Research Communications</i> , 268:390-394 (2000)
	154	SOUYRI, M., "Mpl: from an acute myeloproliferative virus to the isolation of the long sought thrombopoietin," <i>Seminars in Hematology</i> , 35(3):222-231 (1998)
	155	SPAARGAREN <i>et al.</i> , "Antibody-induced Dimerization Activates the Epidermal Growth Factor Receptor Tyrosine Kinase," <i>The J. Biol. Chem.</i> , 266(3):1733-1739 (1981)
	156	TROWBRIDGE, I.S., "Interspecies Spleen-Myeloma Hybrid Producing Monoclonal Antibodies Against Mouse Lymphocyte Surface Glycoprotein, T200," <i>J. Exp. Med.</i> , 148:313-323 (1978)
	157	VAN GEELLEN <i>et al.</i> , "Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines," <i>Br. J. Cancer</i> , 89(2):363-373 (2003)
	158	VERMA <i>et al.</i> , "Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systems," <i>Journal of Immunological Methods</i> , 216:165-181 (1998)
	159	WAKALEE <i>et al.</i> , <i>Ann. Oncol.</i> On-line publication (7/24/2009)
	160	WALCZAK <i>et al.</i> , "TRAIL-R2: A Novel Apoptosis-Mediating Receptor for TRAIL," <i>EMBO J.</i> , 16:5386-5397 (1997)
	161	WARD <i>et al.</i> , "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ," <i>Nature</i> , 341:544-546 (1989)
	162	WELLS, "Perspectives in Biochemistry," <i>Biochemistry</i> , 29(37):8509-8517 (1990)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>14875-0164US1</b>	Application No. <b>10/582,413</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>Toshihiko Ohtomo <i>et al.</i></b>	
		Filing Date <b>October 26, 2006</b>	Group Art Unit <b>1643</b>

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	163	WHITLOW <i>et al.</i> , "Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv," <i>Protein Eng.</i> , 7(8):1017-1026 (1994)
	164	WILEY <i>et al.</i> , "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis," <i>Immunity</i> , 3:673-682 (1995)
	165	WINKLER <i>et al.</i> , "Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody," <i>J. Immunol.</i> , 265:4505-4514 (2000)
	166	XIE <i>et al.</i> , "Direct Demonstration of MuSK Involvement in Acetylcholine Receptor Clustering Through Identification of Agonist ScFv," <i>Nature Biotechnology</i> , 15(8):768-771 (1997)
	167	YAGITA <i>et al.</i> , "TRAIL and its receptors as targets for cancer therapy," <i>Cancer Sci.</i> , 95:777-783 (2004)
	168	YANABU <i>et al.</i> , "Tyrosine phosphorylation and p72syk activation by an anti-glycoprotein lb monoclonal antibody," <i>Blood</i> , 89(5):1590-1598 (1997)
	169	YARDEN <i>et al.</i> , "Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation," <i>Biochemistry</i> , 26(5):1434-1442 (1987)
	170	YELTON <i>et al.</i> , "Fusion of Mouse Myeloma and Spleen Cells," <i>Current Topics in Microbiology and Immunology</i> , 81:1-7 (1978)
	171	U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App. Ser. No. 10/530,696, mailed October 19, 2006, 8 pages
	172	FISH & RICHARDSON P.C., Response to Restriction Requirement dated October 19, 2006, in U.S. App. Ser. No. 10/530,696, filed November 16, 2006, 1 page
	173	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/530,696, mailed December 21, 2006, 19 pages
	174	FISH & RICHARDSON P.C., Amendment in Reply to Office Action dated December 21, 2006 in U.S. App. Ser. No. 10/530,696, filed April 23, 2007, 16 pages
	175	U.S. EXAMINER ANNE GUSSOW, USPTO Final Office Action in U.S. App. Ser. No. 10/530,696, mailed August 8, 2007, 13 pages
	176	U.S. EXAMINER ANNE GUSSOW, USPTO Interview Summary in U.S. App. Ser. No. 10/530,696, mailed November 26, 2007, 3 pages
	177	FISH & RICHARDSON P.C., Amendment in Reply to Office Action dated August 8, 2007 in U.S. App. Ser. No. 10/530,696, filed December 6, 2007, 12 pages
	178	U.S. EXAMINER ANNE GUSSOW, USPTO Advisory Action in U.S. App. Ser. No. 10/530,696, mailed December 14, 2007, 3 pages
	179	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/530,696, mailed February 5, 2008, 9 pages
	180	FISH & RICHARDSON, Amendment in Reply to Action dated February 5, 2008 in U.S. App. Ser. No. 10/530,696, filed August 5, 2008, 7 pages
	181	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/530,696, mailed November 17, 2008, 18 pages
	182	FISH & RICHARDSON, Amendment in Reply to Action dated November 17, 2008 in U.S. App. Ser. No. 10/530,696, filed February 17, 2009, 14 pages
	183	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2003/013063, mailed November 18, 2003, 2 pages

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0164US1	Application No. 10/582,413
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Toshihiko Ohtomo <i>et al.</i>	
		Filing Date October 26, 2006	Group Art Unit 1643

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	184	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2003/013063, dated February 6, 2004, 4 pages
	185	EPO EXAMINER W. BERNHARDT, European Search Report for App. Ser. No. EP 03 75 1456, dated April 4, 2006, 2 pages
	186	U.S. EXAMINER ANNE GUSSOW, USPTO Final Office Action in U.S. App. Ser. No. 10/530,696, mailed June 8, 2009, 10 pages
	187	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Restriction Requirement in U.S. App. Ser. No. 10/548,727, mailed April 12, 2007, 6 pages
	188	FISH & RICHARDSON P.C., Reply to Restriction Requirement dated April 12, 2007 in U.S. App. Ser. No. 10/548,727, filed May 3, 2007, 1 page
	189	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/548,727, mailed August 3, 2007, 21 pages
	190	FISH & RICHARDSON P.C., Reply to Office Action dated August 3, 2007 in U.S. App. Ser. No. 10/548,727, filed January 15, 2008, 15 pages
	191	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Final Office Action in U.S. App. Ser. No. 10/548,727, mailed April 29, 2008, 23 pages
	192	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Advisory Action in U.S. App. Ser. No. 10/548,727, mailed September 24, 2008, 6 pages
	193	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/548,727, mailed January 28, 2009, 16 pages
	194	FISH & RICHARDSON P.C., Reply to Office Action dated January 28, 2009 in U.S. App. Ser. No. 10/548,727, filed June 26, 2009, 9 pages
	195	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/003334, mailed June 15, 2004, 3 pages
	196	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/003334, dated May 2, 2005, 6 pages
	197	U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App. Ser. No. 10/550,934, mailed November 21, 2007, 7 pages
	198	FISH & RICHARDSON P.C., Response to Restriction Requirement dated November 21, 2007 in U.S. App. Ser. No. 10/550,934, filed April 16, 2008, 2 pages
	199	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/550,934, mailed June 12, 2008, 27 pages
	200	FISH & RICHARDSON P.C., Amendment in Reply to Action dated June 12, 2008 in U.S. App. Ser. No. 10/550,934, filed December 12, 2008, 45 pages
	201	U.S. EXAMINER ANNE GUSSOW, USPTO Final Office Action in U.S. App. Ser. No. 10/550,934, mailed March 16, 2009, 19 pages
	202	FISH & RICHARDSON P.C., Amendment in Reply to Action dated March 16, 2009 in U.S. App. Ser. No. 10/550,934, filed September 10, 2009, 75 pages
	203	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/004696, mailed July 27, 2004, 5 pages
	204	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/004696, dated February 9, 2005, 10 pages

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0164US1	Application No. 10/582,413
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Toshihiko Ohtomo <i>et al.</i>	
		Filing Date October 26, 2006	Group Art Unit 1643

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	205	EPO EXAMINER N. FAVRE, European Search Report for App. Ser. No. EP 04 72 4770, dated March 31, 2006, 4 pages
	206	U.S. EXAMINER LORRAINE SPECTOR, USPTO Restriction Requirement in U.S. App. Ser. No. 10/551,504, mailed June 27, 2008, 6 pages
	207	FISH & RICHARDSON P.C., Response to Restriction Requirement dated June 27, 2008 in U.S. App. Ser. No. 10/551,504, filed September 29, 2008, 13 pages
	208	U.S. EXAMINER LORRAINE SPECTOR, USPTO Restriction Requirement in U.S. App. Ser. No. 10/551,504, mailed December 16, 2008, 5 pages
	209	FISH & RICHARDSON P.C., Response to Restriction Requirement dated December 16, 2008 in U.S. App. Ser. No. 10/551,504, filed December 23, 2008, 14 pages
	210	U.S. EXAMINER LORRAINE SPECTOR, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/551,504, mailed April 15, 2009, 35 pages
	211	FISH & RICHARDSON P.C., Amendment in Reply to Action dated April 15, 2009 in U.S. App. Ser. No. 10/551,504, filed August 14, 2009, 19 pages
	212	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018506, mailed March 22, 2005, 3 pages
	213	JAPANESE EXAMINER YOSHIKO KUWAHARA, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/018506, 8 pages
	214	EPO EXAMINER ROBERT RANKIN, European Search Report for App. Ser. No. EP 04 82 0316, dated July 17, 2008, 3 pages
	215	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018499, mailed January 18, 2005, 2 pages
	216	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/018499, dated January 26, 2006, 5 pages
	217	U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,304, mailed November 20, 2008, 7 pages
	218	FISH & RICHARDSON P.C., Response to Restriction Requirement dated November 20, 2008 in U.S. App. Ser. No. 10/582,304, filed December 16, 2008, 3 pages
	219	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/582,304, mailed April 1, 2009, 38 pages
	220	FISH & RICHARDSON P.C., Amendment in Reply to Office Action dated April 1, 2009 in U.S. App. Ser. No. 10/582,304, filed June 30, 2009, 15 pages
	221	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/582,304, mailed September 15, 2009, 22 pages
	222	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018501, mailed March 29, 2005, 2 pages
	223	JAPANESE EXAMINER YOSHIKO KUWAHARA, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/018501, dated November 4, 2005, 7 pages
	224	EPO EXAMINER HELENA DOMINGUES, European Search Report for App. Ser. No. EP 04 82 0311, dated January 28, 2009, 4 pages
	225	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/005152, mailed July 20, 2004, 2 pages

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0164US1	Application No. 10/582,413
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Toshihiko Ohtomo <i>et al.</i>	
		Filing Date October 26, 2006	Group Art Unit 1643

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	226	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/005152, dated February 14, 2005, 6 pages
	227	EPO EXAMINER WIEBKE BERNHARDT, European Search Report for App. Ser. No. EP 04 72 6750, dated February 4, 2008, 3 pages
	228	U.S. EXAMINER BRADLEY DUFFY, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/547,747, mailed June 1, 2009, 41 pages
	229	U.S. EXAMINER ELLY GERALD STOICA, USPTO Restriction Requirement in U.S. App. Ser. No. 11/913,229, mailed July 8, 2009, 6 pages
	230	FISH & RICHARDSON P.C., Response to Restriction Requirement dated July 8, 2009 in U.S. App. Ser. No. 11/913,229, filed August 4, 2009, 1 page
	231	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2006/309890, mailed July 18, 2006, 2 pages
	232	JAPANESE EXAMINER MASASHI HONDA, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2006/309890, dated November 19, 2007, 5 pages
	233	EPO EXAMINER TERESA SOMMERFELD, European Search Report for App. Ser. No. EP 06 74 6578, dated June 25, 2009, 2 pages
	234	U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,654, mailed May 26, 2009, 9 pages
	235	KLARQUIST SPARKMAN, LLP Response to Restriction Requirement dated May 26, 2009 in U.S. App. Ser. No. 10/582,654, filed June 23, 2009, 2 pages
	236	U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Office Action in U.S. App. Ser. No. 10/582,654, mailed September 1, 2009, 36 pages
	237	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Restriction Requirement in U.S. App. Ser. No. 10/399,518, mailed November 25, 2005, 9 pages
	238	FOLEY & LARDNER LLP, Response to Restriction Requirement dated November 25, 2005 in U.S. App. Ser. No. 10/399,518, filed December 23, 2005, 3 pages
	239	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/399,518, mailed March 27, 2006, 38 pages
	240	FOLEY & LARDNER LLP, Amendment in Reply to Action dated March 27, 2006 in U.S. App. Ser. No. 10/399,518, filed September 26, 2006, 26 pages
	241	FOLEY & LARDNER LLP, Supplemental Amendment in Reply to Action dated March 27, 2006 in U.S. App. Ser. No. 10/399,518, filed October 11, 2006, 11 pages
	242	FOLEY & LARDNER LLP, Supplemental Amendment in Reply to Action dated March 27, 2006 in U.S. App. Ser. No. 10/399,518, filed October 13, 2006, 11 pages
	243	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/399,518, mailed December 28, 2006, 29 pages
	244	FOLEY & LARDNER LLP, Amendment in Reply to Action dated December 28, 2006 in U.S. App. Ser. No. 10/399,518, filed May 3, 2007, 22 pages
	245	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Final Office Action in U.S. App. Ser. No. 10/399,518, mailed June 7, 2007, 13 pages
	246	FOLEY & LARDNER LLP, Amendment in Reply to Action dated June 7, 2007 in U.S. App. Ser. No. 10/399,518, filed September 7, 2007, 9 pages

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0164US1	Application No. 10/582,413
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Toshihiko Ohtomo <i>et al.</i>	
		Filing Date October 26, 2006	Group Art Unit 1643

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	247	U.S. EXAMINER DAVID J. BLANCHARD, Advisory Action in U.S. App. Ser. No. 10/399,518, mailed September 27, 2007, 5 pages
	248	U.S. EXAMINER DAVID J. BLANCHARD, Interview Summary in U.S. App. Ser. No. 10/399,518, mailed November 13, 2007, 3 pages
	249	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/399,518, mailed January 31, 2008, 14 pages
	250	FOLEY & LARDNER LLP, Amendment in Reply to Action dated January 31, 2008 in U.S. App. Ser. No. 10/399,518, filed April 30, 2008, 7 pages
	251	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Final Office Action in U.S. App. Ser. No. 10/399,518, mailed August 4, 2008, 8 pages
	252	U.S. EXAMINER DAVID J. BLANCHARD, Advisory Action in U.S. App. Ser. No. 10/399,518, mailed November 7, 2008, 3 pages
	253	FOLEY & LARDNER LLP, Amendment in Reply to Action dated November 7, 2008 in U.S. App. Ser. No. 10/399,518, filed October 22, 2008, 8 pages
	254	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/399,518, mailed February 17, 2009, 12 pages
	255	FOLEY & LARDNER LLP, Amendment in Reply to Action dated February 17, 2009 in U.S. App. Ser. No. 10/399,518, filed May 18, 2009, 26 pages
	256	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018493, mailed March 22, 2005, 2 pages
	257	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/018493, dated December 20, 2005, 7 pages
	258	EPO EXAMINER INGE KALSNER, European Search Report for App. Ser. No. EP 04 82 0305, dated October 6, 2008, 3 pages
	259	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Final Office Action in U.S. App. Ser. No. 10/399,518, mailed September 11, 2009, 24 pages
	260	U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Restriction Requirement in U.S. App. Ser. No. 10/257,864, mailed February 1, 2006, 14 pages
	261	U.S. EXAMINER PENSEE T. DO, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,176, mailed October 19, 2009, 6 pages
	262	FISH & RICHARDSON P.C., Response to Restriction Requirement dated October 19, 2009 in U.S. App. Ser. No. 10/582,176, filed November 4, 2009, 1 page
	263	U.S. EXAMINER ELLY GERALD STOICA, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/913,229, mailed November 3, 2009, 40 pages

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	